Genetics of stroke: A review of recent advances

Expert Review of Molecular Diagnostics

Volumn 8, Issue 4, 2008, Pages 495-513

  Domingues Montanari, Sophie ^a   Mendioroz, Maite ^a   Del Rio Espinola, Alberto ^a   Fernández Cadenas, Israel ^a   Montaner, Joan ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Association study; Genetics; Genome wide linkage; Intracerebral hemorrhage; Meta analysis; Stroke; Therapy

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AGALSIDASE ALFA; AGALSIDASE BETA; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARYLDIALKYLPHOSPHATASE 1; BETA TUBULIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HOMOCYSTEINE; INTERLEUKIN 6; LIPOPROTEIN LIPASE; NITRIC OXIDE; NOTCH3 RECEPTOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVD; PROTEIN KINASE; RECOMBINANT PLASMINOGEN ACTIVATOR; THROMBOCYTE ACTIVATING FACTOR; TISSUE PLASMINOGEN ACTIVATOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; AMINO ACID METABOLISM; ANTICOAGULANT THERAPY; BODY MASS; BRAIN ARTERY; BRAIN HEMORRHAGE; CADASIL; CEREBROVASCULAR ACCIDENT; CHROMOSOME 1; CHROMOSOME 13; CHROMOSOME 17; CHROMOSOME 19; CHROMOSOME 20; CHROMOSOME 21; CHROMOSOME 4; CHROMOSOME 5; CHROMOSOME 6; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME 9; CHROMOSOME MAP; CLINICAL FEATURE; CODON; CRITERION VARIABLE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME REPLACEMENT; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; FABRY DISEASE; FAMILY HISTORY; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC LINKAGE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART DISEASE; HEREDITY; HUMAN; HYPERTENSION; ICELAND; INDUSTRIALIZATION; INFLAMMATION; LIPID METABOLISM; MOLECULAR GENETICS; MULTIFACTORIAL INHERITANCE; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENETICS; POPULATION GENETIC PARAMETERS; PROTEIN PROTEIN INTERACTION; QUANTITATIVE TRAIT LOCUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVASCULARIZATION; REVIEW; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STROKE; SWEDEN; VASCULAR AMYLOIDOSIS;

ANIMALS; CARRIER PROTEINS; CEREBRAL ARTERIES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; GENOME, HUMAN; HUMANS; LINKAGE (GENETICS); MEMBRANE PROTEINS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 46949086397     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.4.495     Document Type: Review

References (150)

1. Dominiczak AF, McBride MW. Genetics of common polygenic stroke. Nat. Genet. 35(2), 116-117(2003).
2. Gretarsdottir S, Thorleifsson G, Reynisdottir ST et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat. Genet. 35(2), 131-138 (2003).
3. International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007).
4. Clayton TA, Lindon JC, Cloarec O et al. Pharmaco - metabonomic phenotyping and personalized drug treatment. Nature 440(7087), 1073-1077(2006).
5. Gabriel RA, Yang GY. Gene therapy in cerebrovascular diseases. Curr. Gene Ther. 7(6), 421-433 (2007).
6. Vila N. A genetic approach to ischemic stroke therapy. Cerebrovasc. Dis. 17(Suppl. 1), 63-69 (2004).
7. Günel M, Lifton RP. Counting strokes. Nat. Genet. 13(4), 384-385 (1996).
8. Kiyohara Y, Kubo M, Kato I et al. Ten-year prognosis of stroke and risk factors for death in a Japanese community: the Hisayama study. Stroke 34(10), 2343-2347 (2003).
9. Otero Palleiro MM, Barbagelata López C. Etiologic subtypes of ischemic stroke in young adults aged 18 to 45 years: a study of a series of 93 patients. Rev. Clin. Esp. 207(4), 158-165 (2007).
10. Lee M, Huang WY, Weng HH, Lee JD, Lee TH. First-ever ischemic stroke in very old Asians: clinical features, stroke subtypes, risk factors and outcome. Eur. Neurol. 58(1), 44-48 (2007).
11. Adams HP Jr, Woolson RF, Clarke WR et al. Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Control. Clin. Trials 18(4), 358-377 (1997).
12. Towfighi A, Greenberg SM, Rosand J. Treatment and prevention of primary intracerebral hemorrhage. Semin. Neurol. 25(4), 445-452 (2005).
13. No authors listed. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 20(10), 1407-1431 (1989).
14. Feigin VL. Stroke epidemiology in the developing world. Lancet 365(9478), 2160-2161 (2005).
15. Thompson DW, Furlan AJ. Clinical epidemiology of stroke. Neurosurg. Clin. N. Am. 8(2), 265-269 (1997).
16. Goldstein LB, Adams R, Alberts MJ et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 113(24), E873-E9230 (2006).
17. Goldstein LB, Adams R, Alberts MJ et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37(6), 1583-1633 (2006).
18. Goldstein LB, Hankey GJ. Advances in primary stroke prevention. Stroke 37(2), 317-319(2006).
19. Hart CL, Hole DJ, Smith GD. Risk factors and 20-year stroke mortality in men and women in the Renfrew/Paisley study in Scotland. Stroke 30(10), 1999-2007 (1999).
20. Marmot MG, Poulter NR. Primary prevention of stroke. Lancet 339(8789), 344-347(1992).
21. Sacco RL. Newer risk factors for stroke. Neurology 57(5 Suppl. 2), S31-S34 (2001).
22. Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of twins and stroke. Stroke23(2), 221-223 (1992).
23. Bak S, Gaist D, Sindrup SH, Skytthe A, Christensen K. Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke 33(3), 769-774 (2002).
24. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke. The Framingham Study. Stroke 24(9), 1366-1371 (1993).
25. Liao D, Myers R, Hunt S et al. Familial history of stroke and stroke risk. The Family Heart Study. Stroke 28(10), 1908-1912 (1997).
26. Schulz UG, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke 35(4), 819-824 (2004).
27. Tournier-Lasserve E. New players in the genetics of stroke. N. Engl. J. Med. 347(21), 1711-1712 (2002).
28. Joutel A, Corpechot C, Ducros A et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383(6602), 707-710(1996).
29. Tournier-Lasserve E, Joutel A, Melki J et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q l2. Nat. Genet. 3(3), 256-259(1993).
30. Baudrimont M, Dubas F, Joutel A, Tournier-Lasserve E, Bousser MG. Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke 24(1), 122-125 (1993).
31. Ruchoux MM, Guerouaou D, Vandenhaute B, Pruvo JP, Vermersch P, Leys D. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol. 89(6), 500-512 (1995).
32. Chabriat H, Tournier-Lasserve E, Vahedi K et al. Autosomal dominant migraine with MRI white-matter abnormalities mapping to the CADASIL locus. Neurology 45(6), 1086-1091 (1995).
33. Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling pathway. Am. J. Hum. Genet. 74(2), 338-347 (2004).
34. Dichgans M, Ludwig H, Müller-Höcker J, Messerschmidt A, Gasser T Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur. J. Hum. Genet. 8(4), 280-285 (2000).
35. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease. Am. J. Hum. Genet. 53(6), 1186-1197(1993).
36. Nance CS, Klein CJ, Banikazemi M et al. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch. Neurol. 63(3), 453-457 (2006).
37. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med. 9(1), 34-45 (2007).
38. Blom D, Speijer D, Linthorst GE, Donker-Koopman WG, Strijland A, Aerts JM. Recombinant enzyme therapy for Fabry disease: absence of editing of human α-galactosidase A mRNA. Am. J. Hum. Genet. 72(1), 23-31 (2003).
39. Clarke JT Narrative review: Fabry disease. Ann. Intern. Med. 146(6), 425-433 (2007).
40. Hendricks HT, Franke CL, Theunissen PH. Cerebral amyloid angiopathy: diagnosis by MRI and brain biopsy. Neurology 40(8), 1308-1310 (1990).
41. Greenberg SM. Genetics of primary intracerebral hemorrhage. J. Stroke Cerebrovasc. Dis. 11(5), 265-271 (2002).
42. Tonk M, Haan J. A review of genetic causes of ischemic and hemorrhagic stroke. J. Neurol. Sci. 257(1-2), 273-279 (2007).
43. Haan J, Kluft C, Leebeek FW, de Bart AC, Buruma OJ, Roos RA. Hereditary cerebral hemorrhage with amyloidosis-Dutch type: a study of fibrinolysis. Thromb. Haemost. 67(1), 16-18 (1992).
44. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol. 49(6), 697-705 (2001).
45. Jensson O, Gudmundsson G, Arnason A et al. Hereditary cystatin C (γ-trace) amyloid angiopathy of the CNS causing cerebral hemorrhage. Acta Neurol. Scand. 76(2), 102-114 (1987).
46. Rubattu S, Volpe M, Kreutz R, Ganten U, Ganten D, Lindpaintner K. Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. Nat. Genet. 13(4), 429-434 (1996).
47. Jeffs B, Clark JS, Anderson NH et al. Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus. Nat. Genet. 16(4), 364-367(1997).
48. Gretarsdottir S, Sveinbjörnsdottir S, Jonsson HH et al. Localization of a susceptibility gene for common forms of stroke to 5q12. Am. J. Hum. Genet. 70(3), 593-603 (2002).
49. Dichgans M. Genetics of ischaemic stroke. Lancet Neurol. 6(2), 149-161 (2007).
50. Rosand J, Bayley N, Rost N, de Bakker PI. Many hypotheses but no replication for the association between PDE4D and stroke. Nat. Genet. 38(10), 1091-1092 (2006).
51. Woo D, Kaushal R, Kissela B et al. Association of phosphodiesterase 4D with ischemic stroke: a population-based case-control study. Stroke 37(2), 371-376 (2006).
52. Nakayama T, Asai S, Sato N, Soma M. Genotype and haplotype association study of the STRK1 region on 5q 12 among Japanese: a case - control study. Stroke 37(1), 69-76 (2006).
53. Saleheen D, Bukhari S, Haider SR et al. Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population. Stroke 36(10), 2275-2277 (2005).
54. Van Rijn MJ, Slooter AJ, Schut AF et al. Familial aggregation, the PDE4D gene, and ischemic stroke in a genetically isolated population. Neurology 65(8), 1203-1209 (2005).
55. Meschia JF, Brott TG, Brown RD Jr et al. Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Ann. Neurol. 58(3), 351-361 (2005).
56. Kuhlenbäumer G, Berger K, Huge A et al. Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort. J. Neurol. Neurosurg. Psychiatry 77(4), 521-524 (2006).
57. Nilsson-Ardnor S, Wiklund PG, Lindgren P et al. Linkage of ischemic stroke to the PDE4D region on 5q in a Swedish population. Stroke 36(8), 1666-1671 (2005).
58. Bevan S, Porteous L, Sitzer M, Markus HS. Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis. Stroke 36(5), 949-953 (2005).
59. Lõhmussaar E, Gschwendtner A, Mueller JC et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 36(4), 731-736 (2005).
60. Kostulas K, Gretarsdottir S, Kostulas V et al. PDE4D and ALOX5AP genetic variants and risk for ischemic cerebrovascular disease in Sweden. J. Neurol. Sci. 263(1-2), 113-117 (2007).
61. Fidani L, Clarimon J, Goulas A et al. Association of phosphodiesterase 4D gene GO haplotype and ischaemic stroke in a Greek population. Eur. J. Neurol. 14(7), 745-749 (2007).
62. Staton JM, Sayer MS, Hankey GJ et al. Association between phosphodiesterase 4D gene and ischaemic stroke. J. Neurol. Neurosurg. Psychiatry 77(9), 1067-1069 (2006).
63. Song Q, Cole JW, O'Connell JR et al. Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study. Hum. Mol. Genet. 15(16), 2468-2478 (2006).
64. Zee RY, Brophy VH, Cheng S, Hegener HH, Erlich HA, Ridker PM. Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case-control evaluation. Stroke 37(8), 2012-2017(2006).
65. Brophy VH, Ro SK, Rhees BK et al. Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status. Stroke 37(6), 1385-1390 (2006).
66. Helgadottir A, Manolescu A, Thorleifsson G et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 36(3), 233-239 (2004).
67. Dixon RA, Diehl RE, Opas E et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343(6255), 282-284(1990).
68. Shen CD, Zhang WL, Sun K, Wang YB, Zhen YS, Hui RT. Interaction of genetic risk factors confers higher risk for thrombotic stroke in male Chinese: a multicenter case-control study. Ann. Hum. Genet. 71(Pt 5), 620-629 (2007).
69. Kaushal R, Pal P, Alwell K et al. Association of ALOX5AP with ischemic stroke: a population-based case-control study. Hum. Genet. 121(5), 601-607 (2007).
70. Zhang WL, Yang XM, Shi J, Sun K,Hui RT. Polymorphism of SG13S114T/A in the ALOX5AP gene and the risk for stroke in a large Chinese cohort. Yi Chuan Xue Bao 33(8), 678-684 (2006).
71. Kajimoto K, Shioji K, Ishida C et al. Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ. J. 69(9), 1029-1034 (2005).
72. Helgadottir A, Gretarsdottir S, St Clair D et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am. J. Hum. Genet. 76(3), 505-509 (2005).
73. Zee RY, Cheng S, Hegener HH, Erlich HA, Ridker PM. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case - control approach. Stroke 37(8), 2007-2011 (2006).
74. Nilsson-Ardnor S, Janunger T, Wiklund PG et al. Genome-wide linkage scan of common stroke in families from northern Sweden. Stroke 38(1), 34-40 (2007).
75. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6(2), 95-108 (2005).
76. Funalot B, Varenne O, Mas JL. A call for accurate phenotype definition in the study of complex disorders. Nat. Genet. 36(1), 3 (2004).
77. Woo D, Sekar P, Chakraborty R et al. Genetic epidemiology of intracerebral hemorrhage. J. Stroke Cerebrovasc. Dis. 14(6), 239-243 (2005).
78. Greenberg SM, Vonsattel JP, Segal AZ et al. Association of apolipoprotein E ε2 and vasculopathy in cerebral amyloid angiopathy. Neurology 50(4), 961-965 (1998).
79. Kaushal R, Woo D, Pal P, Haverbusch M et al. Subarachnoid hemorrhage: tests of association with apolipoprotein E and elastin genes. BMC Med. Genet. 8, 49 (2007).
80. Woo D, Kaushal R, Chakraborty R et al. Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke 36(9), 1874-1879 (2005).
81. Woo D, Sauerbeck LR, Kissela BM et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke 33(5), 1190-1195 (2002).
82. Gould DB, Phalan FC, van Mil SE et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N. Engl. J. Med. 354(14), 1489-1496(2006).
83. Alberts MJ, Davis JP, Graffagnino C et al. Endoglin gene polymorphism as a risk factor for sporadic intracerebral hemorrhage. Ann. Neurol. 41(5), 683-686 (1997).
84. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage. Stroke 29(4), 813-816(1998).
85. Gemmati D, Serino ML, Ongaro A et al. A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am. J. Hematol. 67(3), 183-188 (2001).
86. Nadel JA. Genetics reveals importance of platelet activating factor in asthma and possibly other inflammatory states. J. Clin. Invest. 97(12), 2689-2690 (1996).
87. Slowik A, Turaj W, Dziedzic T et al. DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. Neurology 63(2), 359-361 (2004).
88. Navarro-Núñez L, Lozano ML, Rivera J et al. The association of the β1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica 92(4), 513-518 (2007).
89. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology 53(6), 1308-1311 (1999).
90. Banerjee I, Gupta V, Ganesh S. Association of gene polymorphism with genetic susceptibility to stroke in Asian populations: a meta-analysis. J. Hum. Genet. 52(3), 205-219 (2007).
91. Sudlow C, Martínez González NA, Kim J, Clark C. Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and metaanalyses of 31 studies among 5961 cases and 17,965 controls. Stroke 37(2), 364-370 (2006).
92. Casas JP, Hingorani AD, Bautista LE, Sharma P Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch. Neurol. 61(11), 1652-1661 (2004).
93. Ariyaratnam R, Casas JP, Whittaker J, Smeeth L, Hingorani AD, Sharma P. Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 individuals. PLoS Med. 4(4),E131 (2007).
94. Zee RY, Cook NR, Cheng S et al. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum. Mol Genet. 13(4), 389-396 (2004).
95. Berger K, Stögbauer F, Stoll M et al. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case - control studies. Hum. Genet. 121(2), 169-178 (2007).
96. Keijzer MB, den Heijer M, Blom HJ et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb. Haemost. 88(5), 723-728 (2002).
97. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288(16), 2023-2031 (2002).
98. Baum L, Wong KS, NgHK et al. Methylenetetrahydrofolate reductase gene A222V polymorphism and risk of ischemic stroke. Clin. Chem. Lab. Med. 42(12), 1370-1376 (2004).
99. Choi BO, Kim NK, Kim SH et al. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. Thromb. Res. 111(1-2), 39-44 (2003).
100. Kohara K, Fujisawa M, Ando F et al. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: the NILS-LSA Study. Stroke 34(5), 1130-1135 (2003).
101. Wu Y, Tomon M, Sumino K. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. Kobe J. Med. Sci. 47(6), 255-262 (2001).
102. Morita H, Kurihara H, Tsubaki S et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler. Thromb. Vasc. Biol. 18(9), 1465-1469 (1998).
103. Kelly PJ, Rosand J, Kistler JP et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 59(4), 529-536 (2002).
104. Gu CC, Chang YP, Hunt S C et al. Haplotype association analysis of AGT variants with hypertension-related traits: the HyperGEN study. Hum. Hered. 60(3), 164-176 (2005).
105. Tiret L, Rigat B, Visvikis S et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasmaACE levels. Am. J. Hum. Genet. 51(1), 197-205 (1992).
106. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier E An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86(4), 1343-1346 (1990).
107. Suehiro T, Morita T, Inoue M, Kumon Y, Ikeda Y, Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum. Genet. 115(2), 91-96 (2004).
108. Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359(6396), 641-644 (1992).
109. Sirgo G, Pérez-Vela JL, Morales P et al. Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery. Intensive Care Med. 32(5), 668-675 (2006).
110. Wiklund PG, Nilsson L, Ardnor SN et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 36(8), 1661-1665 (2005).
111. Zhan M, Zhou Y, Han Z. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin. Med. J. (Engl.) 116(11), 1707-1710 (2003).
112. Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 34(12), 2822-2828 (2003).
113. Zhang C, Li J, Li L, Luo B. The study of PAI-1 promotor region gene polymorphism in cerebrovascular disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 18(5), 383-387(2001).
114. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc. Dis. 11(4), 294-299 (2001).
115. Elbaz A, Cambien F, Amarenco P. Plasminogen activator inhibitor genotype and brain infarction. Circulation 103(2), E13-E14 (2001).
116. Endler G, Lalouschek W, Exner M, Mitterbauer G, Häring D, Mannhalter C. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br. J. Haematol. 110(2), 469-471 (2000).
117. Roest M, van der Schouw YT, Banga JD et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 101(1), 67-70 (2000).
118. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb. Haemost. 77(4), 730-734 (1997).
119. Ding J, Nicklas BJ, Fallin MD et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am. Heart J. 152(6), 1109-1115 (2006).
120. Jood K, Ladenvall P, Tjärnlund-Wolf A et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke 36(10), 2077-2081 (2005).
121. van Goor ML, García EG, Leebeek F, Brouwers GJ, Koudstaal P, Dippel D. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case - control study. Thromb. Haemost. 93(1), 92-96 (2005).
122. Chen CH, Eng HL, Chang CJ et al. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J. Lab. Clin. Med. 142(2), 100-105 (2003).
123. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J. Cardiovasc. Risk 9(2), 131-137 (2002).
124. Reiner AP, Schwartz SM, Frank MB et al. Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. Stroke 32(11), 2580-2586(2001).
125. Akar N,Akar E, Yilmaz E, Deda G. Plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation. J. Child Neurol. 16(4), 294-295 (2001).
126. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann. Intern. Med. 140(5), 330-337 (2004).
127. Steen M, Norstrom EA, Tholander AL et al. Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood 103(9), 3381-3387 (2004).
128. Matarín M, Brown WM, Scholz S et al. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol. 6(5), 414-420 (2007).
129. Kubo M, Hata J, Ninomiya T et al. A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat. Genet. 39(2), 212-217(2007).
130. Cupples LA, Arruda HT, Benjamin EJ et al. The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMCMed. Genet. 8(Suppl. 1), S1 (2007).
131. Larson MG, Atwood LD, Benjamin EJ et al. Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med. Genet. 8(Suppl. 1),S5 (2007).
132. McPherson R, Pertsemlidis A, Kavaslar N et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316(5830), 1488-1491 (2007).
133. Bergthorsson JT, Agnarsson BA, Gudbjartsson T et al. A genome-wide study of allelic imbalance in human testicular germ cell tumors using microsatellite markers. Cancer Genet. Cytogenet. 164(1), 1-9 (2006).
134. Abbott A. With your genes? Take one of these, three times a day. Nature 425(6960), 760-762 (2003).
135. Evans WE, McLeod HL. Pharmacogenetics - drug disposition, drug targets, and side effects. N. Engl. J.Med. 348(6), 538-549 (2003).
136. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
137. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W Potential role of pharmacogenetics in reducing adverse drug reactions: a systematic review. JAMA 286(18), 2270-2279 (2001).
138. Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 348(6), 529-537 (2003).
139. No authors listed. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333(24), 1581-1587(1995).
140. Molina CA, Montaner J, Arenillas JF, Ribo M, Rubiera M, Alvarez-Sabín J. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 35(2), 486-490 (2004).
141. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 350(9078), 607-614 (1997).
142. Dubinsky R, Lai SM. Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample. Neurology 66(11), 1742-1744(2006).
143. Sheehan JJ, Tsirka SE. Fibrin-modifying serine proteases thrombin, rt-PA, and plasmin in ischemic stroke: a review. Glia 50(4), 340-350 (2005).
144. Broderick J, Lu M, Jackson C et al. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann. Neurol. 49(6), 736-744 (2001).
145. Ladenvall P, Nilsson S, Jood K, Rosengren A, Blomstrand C, Jern C. Genetic variation at the human tissue-type plasminogen activator (rt-PA) locus: haplotypes and analysis of association to plasma levels of rt-PA. Eur. J. Hum. Genet. 11(8), 603-610(2003).
146. Montaner J, Fernández-Cadenas I, Molina CA et al. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke 34(12), 2851-2855 (2003).
147. Fernández-Cadenas I, Alvarez Sabín J, Molina CA et al. ApoE genotype influences on efficacy and safety of thrombolytic treatment for ischemic stroke. Neurologia 21(4), 176-180(2006).
148. Fernández-Cadenas I, Molina CA, Alvarez-Sabín J et al. ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neurosci. Lett. 398(3), 167-171 (2006).
149. González-Conejero R, Fernández-Cadenas I, Iniesta JA et al. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 37(9), 2288-2293 (2006).
150. Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M et al. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J. Thromb. Haemost. 5(9), 1862-1868 (2007).